ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Rare Case of Mycosis Fungoides in Children: Case Report and Review of Literature

22 June 09:45

Purpose of the Paper: To describe a case of a rare cutaneous lymphoma in a pediatric patient and to discuss modern approaches to diagnosis and treatment.

Key Points: Mycosis fungoides (MF) is a type of malignant cutaneous lymphoma, which is very rare in children. This paper describes a clinical case of MF in a 14-year-old child, who had received various treatments for this condition, including a bone marrow transplant. In addition, the authors discuss modern approaches to diagnosing and treating this disorder.

Conclusion: Cutaneous lymphomas may occur in children and require verification through a thorough morphological investigation. Compared to adults, children may require more intensive treatment.

N. V. Myakova — Dmitry Rogachyov Federal Scientific and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow. E-mail: Natalya.Myakova@fccho-moscow.ru

D. S. Abramov — Dmitry Rogachyov Federal Scientific and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow. E-mail: Dmitry.Abramov@fccho-moscow.ru

A. V. Pshonkin — Dmitry Rogachyov Federal Scientific and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow. E-mail: alexey.pshonkin@fccho-moscow.ru

D. M. Konovalov — Dmitry Rogachyov Federal Scientific and Clinical Center for Pediatric Hematology, Oncology and Immunology, Moscow. E-mail: dmitry.konovalov@fccho-moscow.ru

Доктор.ру
22 June 09:45
LITERATURE
  1. Brender C., Nielsen M., Kaltoft K., Mikkelsen G. et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma // Blood. 2001. Vol. 97. N 4. P. 1056–1062.
  2. Diamandidou E., Colome M., Fayad L., Duvic M. et al. Prognostic factor analysis in mycosis fungoides/Sézary syndrome // J. Am. Acad. Dermatol. 1999. Vol. 40. N 6. P. 914–924.
  3. Eriksen K. W., Kaltoft K., Mikkelsen G., Nielsen M. et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells // Leukemia. 2001. Vol. 15. N 5. P. 787–793.
  4. Everett M. A. Early diagnosis of Mycosis fungoides: vacuolar interface dermatitis // J. Cutan. Pathol. 1985. Vol. 12. N 3–4. P. 271–278.
  5. Ferri F. Ferri's Clinical Advisor. Philadelphia: Elsevier, 2015. P. 794–795.e6.
  6. Gjerdrum L. M., Woetmann A., Odum N., Burton C. M. et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival // Leukemia. 2007. Vol. 21. N 12. P. 2512–2518.
  7. Goudie R. B., Karim S., AlBadri A. T., Gudgeon J. et al. Widespread neoplastic involvement of skin in the plaque stage of mycosis fungoides // J. Pathol. 1992. Vol. 167. Suppl. P. A125.
  8. Hoppe R. T., Medeiros L. J., Warnke R. A., Wood G. S. CD8-positive tumor-infiltrating lymphocytes influence the survival of patients with mycosis fungoides // J. Am. Acad. Dermatol. 1995. Vol. 32. N 3. P. 448–453.
  9. Horwitz S. M., Olsen E. A., Duvic M., Porcu P. et al. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach // J. Natl. Compr. Canc. Netw. 2008. Vol. 6. N 4. P. 436–442.
  10. Hwang S. T., Janik J. E., Jaffe E. S., Wilson W. H. Mycosis fungoides and Sézary syndrome // Lancet. 2008. Vol. 371. N 9616. P. 945–957.
  11. Izban K. F., Ergin M., Qin J.-Z., Martinez R. L. et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis // Hum. Pathol. 2000. Vol. 31. N 12. P. 1482–1490.
  12. Kim Y. H., Bishop K., Varghese A., Hoppe R. T. et al. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome // Arch. Dermatol. 1995. Vol. 131. N 9. P. 1003–1008.
  13. Kim Y., Chow S., Varghese A., Hoppe R. T. Clinical characterization and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides // Arch. Dermatol. 1999. Vol. 135. N 1. P. 26–32.
  14. Kim Y., Jensen R., Watanabe G., Varghese A. et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis // Arch. Dermatol. 1996. Vol. 132. N 11. P. 1309–1313.
  15. King-Ismael D., Ackerman A. B. Guttate parapsoriasis/digitate dermatosis (small plaque parapsoriasis) is mycosis fungoides // Am. J. Dermatopathol. 1992. Vol. 14. N 6. P. 518–535.
  16. Koh H. K., Charif M., Weinstock M. A. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma // Hematol. Oncol. Clin. North. Am. 1995. Vol. 9. N 5. P. 943–960.
  17. Krathen M., Sundram U., Bashey S. Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoudes with variable CD30 expression // ASH Annual Meeting Abstracts. 2012. Vol. 120. N 21. P. 797.
  18. Kreuter A., Bischoff S., Skrygan M., Wieland U. et al. High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides // Arch. Dermatol. 2008. Vol. 144. N 8. P. 1011–1016.
  19. Liu V., McKee P. H. Cutaneous T-cell lymphoproliferative disorders: approach for the surgical pathologist: recent advances and clarification of confused issues // Adv. Anat. Pathol. 2002. Vol. 9. N 2. P. 79–100.
  20. Lorincz A. L. Cutaneous T-cell lymphoma (mycosis fungoides) // Lancet. 1996. Vol. 347. N 9005. P. 871–876.
  21. Mao X., Lillington D., Scarisbrick J. J., Mitchell T. et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides // Br. J. Dermatol. 2002. Vol. 147. N 3. P. 464–475.
  22. Marti R. M., Estrach T., Reverter J. C., Mascaró J. M. et al. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma // Arch. Dermatol. 1991. Vol. 127. N 10. P. 1511–1516.
  23. Meissner K., Michaelis K., Rehpenning W., Löning T. Epidermal Langerhan's cell densities influence survival in mycosis fungoides and Sézary syndrome // Cancer. 1990. Vol. 65. N 9. P. 2069–2073.
  24. Nickoloff B. J. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides // Am. J. Dermatopathol. 1988. Vol. 10. N 6. P. 469–477.
  25. Nielsen M., Nissen M. H., Gerwein J., Zocca M. B. et al. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3 // Blood. 2002. Vol. 99. N 3. P. 973–977.
  26. Olsen E., Vonderheid E., Pimpinelli N., Willemze R. et al.; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) // Blood. 2007. Vol. 110. N 6. P. 1713–1722.
  27. Prince Y. M., Whittaker S., Hoppe R. How I treat mycosis fungoides and Sézary syndrome // Blood. 2009. Vol. 114. N 20. P. 4337–4353.
  28. Ralfkiaer E., Cerroni L., Sander C. A. et al. Mycosis fungoides // WHO classification of tumours of haematopoietic and lymphoid tissues / S. H. Swerdlow, E. Campo, N. L. Harris, eds. Lyons: IARC Press, 2008. P. 296–298.
  29. Sanchez J. L., Ackerman A. B. The patch stage of mycosis fungoides. Criteria for histologic diagnosis // Am. J. Dermatopathol. 1979. Vol. 1. N 1. P. 5–26.
  30. Scarisbrick J., Child F., Clift A., Sabroe R. et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma // Br. J. Dermatol. 2001. Vol. 144. N 5. P. 1010–1015.
  31. Smith N. P. Histologic criteria for early diagnosis of cutaneous T-cell lymphoma // Dermatol. Clin. 1994. Vol. 12. N 2. P. 315–322.
  32. Swerdlow S. H., Campo E., Harris N. L., Jaffe E. S. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyons: IARC Press, 2008. 439 p.
  33. Tracey L., Villuendas R., Dotor A. M., Spiteri I. et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study // Blood. 2003. Vol. 102. N 3. P. 1042–1050.
  34. Tsimberidou A., Giles F., Duvic M., Fayad L. et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies, update of an M. D. Anderson Cancer center series // Cancer. 2004. Vol. 100. N 2. P. 342–349.
  35. Van Doorn R., Van Haselen C. W., van Voorst Vader P. C., Geerts M. L. et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients // Arch. Dermatol. 2000. Vol. 136. N 4. P. 504–510.
  36. Vega F., Luthra R., Medeiros J., Dunmire V. et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course // Blood. 2002. Vol. 100. N 9. P. 3369–3373.
  37. Wain E. M., Orchard G., Whittaker S., Spittle M. F. et al. Outcome in 34 patients with juvenile-onset mycosis fungoides // Cancer. 2003. Vol. 98. N 10. P. 2282–2289.
  38. Wasik M. A., Vonderheid E. C., Bigler R. D., Marti R. et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma // Arch. Dermatol. 1996. Vol. 132. N 1. P. 42–47.
  39. Weiss L. M., Hu E., Wood G. S., Moulds C. et al. Clonal rearrangements of T-cell receptor genes in mycosis fungoides and dermatopathic lymphadenopathy // N. Engl. J. Med. 1985. Vol. 313. N 9. P. 539–544.
  40. Whittaker S. J., Smith N. P., Jones R. R., Luzzatto L. Analysis of beta, gamma and delta T-cell receptor genes in mycosis fungoides and Sézary syndrome // Cancer. 1991. Vol. 68. N 7. P. 1572–1582.
  41. Willemze R., Kerl H., Sterry W., Berti E. et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer // Blood. 1997. Vol. 90. N 1. P. 354–371.
  42. Wollina U., Dummer R., Brockmeyer N., Konrad H. et al. Multicener study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma // Cancer. 2003. Vol. 98. N 5. P. 993–1001.
  43. Wood G. S., Tung R. M., Haeffner A. C., Crooks C. F. et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sézary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE) // J. Invest. Dermatol. 1994. Vol. 103. N 1. P. 34–41.
  44. Zelickson B. D., Peters M. S., Muller S. A., Thibodeau S. N. et al. T-cell receptor gene rearrangement analysis: cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders // J. Am. Acad. Dermatol. 1991. Vol. 25. N 5. P. 787–796.
  45. Zinzani P. L., Baliva G., Magagnoli M., Bendandi M. et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients // J. Clin. Oncol. 2000. Vol. 18. N 13. P. 2603–2606.
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
12 March 18:32, Obstetrics
N.V. Bashmakova, A.E. Aitov, N.V. Kosovtsоva, G.N. Chistyakova, I.I. Remizova
Efficiency Assessment of Fetoscope Laser Coagulation of Placental Anastomosis in Women Pregnant with Monochorionic Diamniotic Twins
Doctor.Ru Gynecology. Vol. 20, No. 1 (2021)
12 March 18:22, Obstetrics
Zh.I. Glinkina, E.V. Kulakova, I.I. Vityazeva, E.I. Pomerantseva, N.V. Oparina, V.S. Kuzmicheva
The Role of High Throughput Sequencing in Pre-implantation Genetic Testing for Identification of Genetic Variations in IVF Patients
Doctor.Ru Gynecology. Vol. 20, No. 1 (2021)

News